RecruitingNot ApplicableNCT05187819

Blood-based Biomarkers for Diagnosis of Alzheimer's

Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice

Sponsor

Helse Stavanger HF

Enrollment

300 participants

Start Date

Jun 1, 2023

Study Type

INTERVENTIONAL

Conditions

Dementia Alzheimers

Summary

Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD. This project will assess the predictive value of these tests in a general practice population. The hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.

Eligibility

Min Age: 40 YearsMax Age: 100 Years

Inclusion Criteria1

Participants suspected by their GP to have possible dementia, based on history, clinical examination and/or cognitive screening

Exclusion Criteria3

Lack of capacity for consent as judged by the GP.
Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.
Patients not wanting to be referred to the memory outpatient clinic.